Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)

Next Previous
X
Search
Trial Profile

A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
  • Indications Carcinoma; Cervical cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
  • Focus Adverse reactions
  • Sponsors Gradalis

    • Most Recent Events

    • 04 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2022 Results published in the Gradalis Media Release
    • 03 Feb 2021 Planned End Date changed from 1 Feb 2021 to 30 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top